Reuters Health: Factor VII Curbs Bleeding in Non-Hemophiliac Trauma, Surgical Patients
Use of recombinant activated factor VII (rFVIIa) reduces the need for blood transfusion in patients without hemophilia and may also reduce mortality, according to pooled data from randomized placebo-controlled trials involving more than 3000 participants, Canadian researchers report. "I had found it to be effective in some combat situations in Afghanistan," senior investigator Dr. Vivian C. McAlister told Reuters Health.
Reuters Health. "Reuters Health: Factor VII Curbs Bleeding in Non-Hemophiliac Trauma, Surgical Patients" 2008
Available at: http://works.bepress.com/vivianmcalister/34